首页> 外文期刊>Nephro-Urology Monthly >New Independent Thermobalancing Treatment with Therapeutic Device for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
【24h】

New Independent Thermobalancing Treatment with Therapeutic Device for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

机译:慢性前列腺炎/慢性盆腔疼痛综合征的治疗装置新的独立热平衡疗法

获取原文
           

摘要

Background: Medications, alternative and complementary treatments for type-III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) are used frequently. The aim of this article is to define thermobalancing therapy as an independent treatment for internal diseases, such as CP/CPPS. Methods: The effect of thermobalancing therapy (TT) by using Dr. Allen’s therapeutic device-(DATD) on patients with CP/CPPS was investigated. National institute of health chronic prostatitis symptom index (NIH-CPSI) scores, prostatic volume (PV), and maximum urinary flow rate (Qmax) were measured in one group of 45 patients who underwent TT and a control group that did not have TT. These all parameters were compared between groups. Results: No significant difference was found at baseline evaluation in treatment and control groups with regard to age, NIH-CPSI score, PV or Qmax. In the treatment group pain score decreased and quality of life (QoL) improved significantly, whereas in the control group no changes. TT reduced PV and increased Qmax significantly, whereas in the control group TT did not elicit significant changes in PV and Qmax. Conclusions: The study has explored that TT with DATD as monotherapy for CP/CPPS patients: (i) reduces pain dramatically and improves QoL; (ii) reduces PV and increases Qmax. None of the patients who received TT suffered side effects and the cost of TT compares favourably with the cost of conventional treatment. Thus, TT could be recommended as a new independent treatment for CP/CPPS.
机译:背景:III型慢性前列腺炎/慢性盆腔疼痛综合征(CP / CPPS)的药物,替代治疗和补充治疗经常被使用。本文的目的是将热平衡疗法定义为针对内部疾病(如CP / CPPS)的独立疗法。方法:研究了使用艾伦博士的治疗仪(DATD)对CP / CPPS患者进行热平衡疗法(TTTD)的效果。美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)评分,前列腺体积(PV)和最大尿流率(Qmax)在一组进行TT的45例患者和未进行TT的对照组中进行了测量。在组之间比较所有这些参数。结果:在基线评估中,治疗组和对照组在年龄,NIH-CPSI评分,PV或Qmax方面无显着差异。在治疗组中,疼痛评分降低,生活质量(QoL)明显改善,而对照组则没有变化。 TT降低PV并显着增加Qmax,而对照组TT并未引起PV和Qmax的显着变化。结论:该研究已经探索了将DATD与TT结合作为CP / CPPS患者的单一疗法:(i)显着减轻疼痛并改善QoL; (ii)降低PV并增加Qmax。接受TT治疗的患者均无副作用,且TT的费用可与常规治疗费用相比。因此,可以推荐将TT作为CP / CPPS的一种新的独立治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号